Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical usefulness and influence on oesophageal motility of pyridostigmine in systemic sclerosis-related dysphagia
2020-004723-17Phase 2Completed
- Sponsor
- UZ Brussel
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of pyridostigmine in dysphagia, systemic sclerosis (SSc) and esophageal dysmotility, sponsored by UZ Brussel. Primary endpoint: Improvement of dysphagia. Started Jan 2021; status: completed.
02
Drugs
pyridostigmine
03
Conditions
dysphagiasystemic sclerosis (SSc)esophageal dysmotility
Beyond the preview
Go deeper on 2020-004723-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004723-17.